Skip to main content
Erschienen in: Die Dermatologie 8/2021

05.07.2021 | Acne inversa | Leitthema

Epidemiologie, Patientenlebensqualität und Behandlungskosten der Hidradenitis suppurativa/Acne inversa

verfasst von: Dr. N. Kirsten, V. Frings, G. D. Nikolakis, Dr. D. Presser, Prof. M. Goebeler, Prof. C. C. Zouboulis, Prof. M. Augustin

Erschienen in: Die Dermatologie | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hidradenitis suppurativa (HS)/Acne inversa (AI) geht mit zahlreichen und relevanten Einschränkungen der Lebensqualität für die Betroffenen und ihre Angehörigen einher. Literaturangaben zur Prävalenz der HS variieren erheblich, sie ist jedoch wahrscheinlich höher als in früheren Publikationen angenommen. Die Versorgung der HS geht mit hohen Kosten für das Gesundheitssystem und die Betroffenen einher. Die Einführung der Biologikatherapie hat zu weiteren Kosten, jedoch auch erheblichem Mehrnutzen in der Versorgung geführt. Angesichts der Komplexität von Diagnostik und Therapie besteht ein besonderer Bedarf an optimierten Versorgungskonzepten, um die Last für die Betroffenen, ihre Angehörigen und das Gesundheitssystem zu reduzieren.
Literatur
1.
Zurück zum Zitat Alavi A, Farzanfar D, Lee RK et al (2018) The contribution of malodour in quality of life of patients with hidradenitis suppurativa. J Cutan Med Surg 22:166–174PubMedCrossRef Alavi A, Farzanfar D, Lee RK et al (2018) The contribution of malodour in quality of life of patients with hidradenitis suppurativa. J Cutan Med Surg 22:166–174PubMedCrossRef
2.
Zurück zum Zitat Argyropoulou M, Kanni T, Kyprianou M et al (2019) Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort. Br J Dermatol 180:1161–1168PubMedCrossRef Argyropoulou M, Kanni T, Kyprianou M et al (2019) Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort. Br J Dermatol 180:1161–1168PubMedCrossRef
3.
Zurück zum Zitat Balieva F, Kupfer J, Lien L et al (2017) The burden of common skin diseases assessed with the EQ5D: a European multicentre study in 13 countries. Br J Dermatol 176:1170–1178PubMedCrossRef Balieva F, Kupfer J, Lien L et al (2017) The burden of common skin diseases assessed with the EQ5D: a European multicentre study in 13 countries. Br J Dermatol 176:1170–1178PubMedCrossRef
4.
Zurück zum Zitat Chernyshov PV, Zouboulis CC, Tomas-Aragones L et al (2021) Quality of life in hidradenitis suppurativa. An update. Int J Environ Res Public Health 18:6131PubMedPubMedCentralCrossRef Chernyshov PV, Zouboulis CC, Tomas-Aragones L et al (2021) Quality of life in hidradenitis suppurativa. An update. Int J Environ Res Public Health 18:6131PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Cosmatos I, Matcho A, Weinstein R et al (2013) Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 69:819PubMedCrossRef Cosmatos I, Matcho A, Weinstein R et al (2013) Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 69:819PubMedCrossRef
6.
Zurück zum Zitat Cuenca-Barrales C, Molina-Leyva A (2020) Risk factors of sexual dysfunction in patients with hidradenitis suppurativa: a cross-sectional study. Dermatology 236:37–45PubMedCrossRef Cuenca-Barrales C, Molina-Leyva A (2020) Risk factors of sexual dysfunction in patients with hidradenitis suppurativa: a cross-sectional study. Dermatology 236:37–45PubMedCrossRef
7.
Zurück zum Zitat Fernandez JM, Rizvi OH, Marr KD et al (2021) Itch and pain by lesion morphology in hidradenitis suppurativa patients. Int J Dermatol 60:e56–e59PubMedCrossRef Fernandez JM, Rizvi OH, Marr KD et al (2021) Itch and pain by lesion morphology in hidradenitis suppurativa patients. Int J Dermatol 60:e56–e59PubMedCrossRef
8.
Zurück zum Zitat Frings VG, Bauer B, Gloditzsch M et al (2019) Assessing the psychological burden of patients with hidradenitis suppurativa. Eur J Dermatol 29:294–301PubMed Frings VG, Bauer B, Gloditzsch M et al (2019) Assessing the psychological burden of patients with hidradenitis suppurativa. Eur J Dermatol 29:294–301PubMed
9.
Zurück zum Zitat Garcovich S, Muratori S, Moltrasio C et al (2020) Prevalence of neuropathic pain and related characteristics in hidradenitis suppurativa: a cross-sectional study. J Clin Med 9(12):4046PubMedCentral Garcovich S, Muratori S, Moltrasio C et al (2020) Prevalence of neuropathic pain and related characteristics in hidradenitis suppurativa: a cross-sectional study. J Clin Med 9(12):4046PubMedCentral
10.
Zurück zum Zitat Garg A, Kirby JS, Lavian J et al (2017) Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol 153:760–764PubMedPubMedCentralCrossRef Garg A, Kirby JS, Lavian J et al (2017) Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol 153:760–764PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Garg A, Papagermanos V, Midura M et al (2018) Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: a population-based analysis in the United States. J Am Acad Dermatol 79:495–500.e1PubMedCrossRef Garg A, Papagermanos V, Midura M et al (2018) Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: a population-based analysis in the United States. J Am Acad Dermatol 79:495–500.e1PubMedCrossRef
12.
Zurück zum Zitat Gaspar K, Hunor Gergely L, Jenei B et al (2021) Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res 9:1–10 Gaspar K, Hunor Gergely L, Jenei B et al (2021) Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res 9:1–10
13.
Zurück zum Zitat Janse IC, Deckers IE, Van Der Maten AD et al (2017) Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. Br J Dermatol 176:1042–1047PubMedCrossRef Janse IC, Deckers IE, Van Der Maten AD et al (2017) Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. Br J Dermatol 176:1042–1047PubMedCrossRef
14.
Zurück zum Zitat Jfri AND, O’brien E, Gulliver W, Nikolakis G, Zouboulis CC (2021) Prevalence of hidradenitis suppurativa: A systematic review and meta-regression study. JAMA Dermatol :e211677 Jfri AND, O’brien E, Gulliver W, Nikolakis G, Zouboulis CC (2021) Prevalence of hidradenitis suppurativa: A systematic review and meta-regression study. JAMA Dermatol :e211677
15.
Zurück zum Zitat Kaaz K, Szepietowski JC, Matusiak L (2018) Influence of itch and pain on sleep quality in patients with hidradenitis suppurativa. Acta Derm Venereol 98:757–761PubMedCrossRef Kaaz K, Szepietowski JC, Matusiak L (2018) Influence of itch and pain on sleep quality in patients with hidradenitis suppurativa. Acta Derm Venereol 98:757–761PubMedCrossRef
16.
Zurück zum Zitat Karagiannidis I, Nikolakis G, Zouboulis CC (2016) Endocrinologic aspects of hidradenitis suppurativa. Dermatol Clin 34:45–49PubMedCrossRef Karagiannidis I, Nikolakis G, Zouboulis CC (2016) Endocrinologic aspects of hidradenitis suppurativa. Dermatol Clin 34:45–49PubMedCrossRef
17.
Zurück zum Zitat Kirby JS, Miller JJ, Adams DR et al (2014) Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol 150:937–944PubMedCrossRef Kirby JS, Miller JJ, Adams DR et al (2014) Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol 150:937–944PubMedCrossRef
18.
Zurück zum Zitat Kirsten NOM, Bechara F et al (2019) HS-QoL: Disease specific instrument to assess quality of life in patients with hidradenitis suppurativa. Oral presentation; 8th Conference of the European Hidradenitis Suppurativa Foundation, Wroclaw, 02.2019 Kirsten NOM, Bechara F et al (2019) HS-QoL: Disease specific instrument to assess quality of life in patients with hidradenitis suppurativa. Oral presentation; 8th Conference of the European Hidradenitis Suppurativa Foundation, Wroclaw, 02.2019
19.
Zurück zum Zitat Kirsten N, Petersen J, Hagenstrom K et al (2020) Epidemiology of hidradenitis suppurativa in Germany—an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol 34:174–179PubMedCrossRef Kirsten N, Petersen J, Hagenstrom K et al (2020) Epidemiology of hidradenitis suppurativa in Germany—an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol 34:174–179PubMedCrossRef
20.
Zurück zum Zitat Kirsten N, Zander N, Augustin M (2021) Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res 313:95–99PubMedCrossRef Kirsten N, Zander N, Augustin M (2021) Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res 313:95–99PubMedCrossRef
21.
Zurück zum Zitat Kurek A, Peters EM, Chanwangpong A et al (2012) Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol 67:422–428, 428 e421PubMedCrossRef Kurek A, Peters EM, Chanwangpong A et al (2012) Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol 67:422–428, 428 e421PubMedCrossRef
22.
Zurück zum Zitat Kurzen H, Kurokawa I, Jemec GB et al (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:455–456 (discussion 457–472)PubMedCrossRef Kurzen H, Kurokawa I, Jemec GB et al (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:455–456 (discussion 457–472)PubMedCrossRef
23.
Zurück zum Zitat Lam M, Lai C, Almuhanna N et al (2020) Hidradenitis suppurativa and down syndrome: a systematic review and meta-analysis. Pediatr Dermatol 37:1044–1050PubMedCrossRef Lam M, Lai C, Almuhanna N et al (2020) Hidradenitis suppurativa and down syndrome: a systematic review and meta-analysis. Pediatr Dermatol 37:1044–1050PubMedCrossRef
24.
Zurück zum Zitat Lazic T, Li Q, Frank M et al (2012) Extending the phenotypic spectrum of keratitis-ichthyosis-deafness syndrome: report of a patient with GJB2 (G12R) Connexin 26 mutation and unusual clinical findings. Pediatr Dermatol 29:349–357PubMedCrossRef Lazic T, Li Q, Frank M et al (2012) Extending the phenotypic spectrum of keratitis-ichthyosis-deafness syndrome: report of a patient with GJB2 (G12R) Connexin 26 mutation and unusual clinical findings. Pediatr Dermatol 29:349–357PubMedCrossRef
25.
Zurück zum Zitat Lee JH, Kwon HS, Jung HM et al (2018) Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol 32:1784–1790PubMedCrossRef Lee JH, Kwon HS, Jung HM et al (2018) Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol 32:1784–1790PubMedCrossRef
26.
Zurück zum Zitat Li M, Hunt MJ, Commens CA (1997) Hidradenitis suppurativa, Dowling Degos disease and perianal squamous cell carcinoma. Australas J Dermatol 38:209–211PubMedCrossRef Li M, Hunt MJ, Commens CA (1997) Hidradenitis suppurativa, Dowling Degos disease and perianal squamous cell carcinoma. Australas J Dermatol 38:209–211PubMedCrossRef
27.
Zurück zum Zitat Marzano AV, Ceccherini I, Gattorno M et al (2014) Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine 93:e187PubMedPubMedCentralCrossRef Marzano AV, Ceccherini I, Gattorno M et al (2014) Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine 93:e187PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Matusiak L, Bieniek A, Szepietowski JC (2010) Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 62:706–708, 708 e701PubMedCrossRef Matusiak L, Bieniek A, Szepietowski JC (2010) Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 62:706–708, 708 e701PubMedCrossRef
29.
Zurück zum Zitat Matusiak L, Szczech J, Kaaz K et al (2018) Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol 98:191–194PubMedCrossRef Matusiak L, Szczech J, Kaaz K et al (2018) Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol 98:191–194PubMedCrossRef
30.
Zurück zum Zitat Mclellan C, Sisic M, Oon HH et al (2018) Preliminary validation of the HS-QoL: a quality-of-life measure for hidradenitis suppurativa. J Cutan Med Surg 22:142–146PubMedCrossRef Mclellan C, Sisic M, Oon HH et al (2018) Preliminary validation of the HS-QoL: a quality-of-life measure for hidradenitis suppurativa. J Cutan Med Surg 22:142–146PubMedCrossRef
31.
Zurück zum Zitat Molina-Leyva A, Cuenca-Barrales C (2020) Pruritus and malodour in patients with hidradenitis suppurativa: impact on quality of life and clinical features associated with symptom severity. Dermatology 236:59–65PubMedCrossRef Molina-Leyva A, Cuenca-Barrales C (2020) Pruritus and malodour in patients with hidradenitis suppurativa: impact on quality of life and clinical features associated with symptom severity. Dermatology 236:59–65PubMedCrossRef
32.
Zurück zum Zitat Nguyen MT, Borchers A, Selmi C et al (2012) The SAPHO syndrome. Semin Arthritis Rheum 42:254–265PubMedCrossRef Nguyen MT, Borchers A, Selmi C et al (2012) The SAPHO syndrome. Semin Arthritis Rheum 42:254–265PubMedCrossRef
33.
Zurück zum Zitat Nielsen RM, Lindso Andersen P, Sigsgaard V et al (2020) Pain perception in patients with hidradenitis suppurativa. Br J Dermatol 182:166–174PubMedCrossRef Nielsen RM, Lindso Andersen P, Sigsgaard V et al (2020) Pain perception in patients with hidradenitis suppurativa. Br J Dermatol 182:166–174PubMedCrossRef
34.
Zurück zum Zitat Nikolakis G, Kaleta KP, Vaiopoulos AG et al (2020) Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: Different faces of the same disease? A systematic review. Dermatology 9:1–25 Nikolakis G, Kaleta KP, Vaiopoulos AG et al (2020) Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: Different faces of the same disease? A systematic review. Dermatology 9:1–25
35.
Zurück zum Zitat Nikolakis G, Karagiannidis I, Vaiopoulos AG et al (2020) Endokrine Mechanismen bei der Pathophysiologie der Hidradenitis suppurativa. Hautarzt 71:762–771PubMedCrossRef Nikolakis G, Karagiannidis I, Vaiopoulos AG et al (2020) Endokrine Mechanismen bei der Pathophysiologie der Hidradenitis suppurativa. Hautarzt 71:762–771PubMedCrossRef
36.
Zurück zum Zitat Nikolakis GKK, Vaiopoulos A, Kaleta K, Talas J, Becker M, Zouboulis CC (2021) Successful application of secukinumab for the treatment of PsAPSASH syndrome, an alternative phenotype of syndromic hidradenitis suppurativa. F1000 Research 10:381CrossRefPubMedPubMedCentral Nikolakis GKK, Vaiopoulos A, Kaleta K, Talas J, Becker M, Zouboulis CC (2021) Successful application of secukinumab for the treatment of PsAPSASH syndrome, an alternative phenotype of syndromic hidradenitis suppurativa. F1000 Research 10:381CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Onderdijk AJ, Van Der Zee HH, Esmann S et al (2013) Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 27:473–478PubMedCrossRef Onderdijk AJ, Van Der Zee HH, Esmann S et al (2013) Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 27:473–478PubMedCrossRef
38.
Zurück zum Zitat Phan K, Charlton O, Smith SD (2020) Hidradenitis suppurativa and polycystic ovarian syndrome: systematic review and meta-analysis. Australas J Dermatol 61:e28–e33PubMedCrossRef Phan K, Charlton O, Smith SD (2020) Hidradenitis suppurativa and polycystic ovarian syndrome: systematic review and meta-analysis. Australas J Dermatol 61:e28–e33PubMedCrossRef
39.
Zurück zum Zitat Richter T, Nestler-Parr S, Babela R et al (2015) Rare disease terminology and definitions—a systematic global review: report of the ISPOR rare disease special interest group. Value Health 18:906–914PubMedCrossRef Richter T, Nestler-Parr S, Babela R et al (2015) Rare disease terminology and definitions—a systematic global review: report of the ISPOR rare disease special interest group. Value Health 18:906–914PubMedCrossRef
40.
Zurück zum Zitat Sampogna F, Fania L, Mastroeni S et al (2020) Correlation between depression, quality of life and clinical severity in patients with hidradenitis suppurativa. Acta Derm Venereol 100:adv319PubMed Sampogna F, Fania L, Mastroeni S et al (2020) Correlation between depression, quality of life and clinical severity in patients with hidradenitis suppurativa. Acta Derm Venereol 100:adv319PubMed
41.
Zurück zum Zitat Saunte DM, Boer J, Stratigos A et al (2015) Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 173:1546–1549PubMedCrossRef Saunte DM, Boer J, Stratigos A et al (2015) Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 173:1546–1549PubMedCrossRef
42.
Zurück zum Zitat Theut Riis P, Pedersen OB, Sigsgaard V et al (2019) Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study. Br J Dermatol 180:774–781PubMedCrossRef Theut Riis P, Pedersen OB, Sigsgaard V et al (2019) Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study. Br J Dermatol 180:774–781PubMedCrossRef
43.
Zurück zum Zitat Thorlacius L, Cohen AD, Gislason GH et al (2018) Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol 138:52–57PubMedCrossRef Thorlacius L, Cohen AD, Gislason GH et al (2018) Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol 138:52–57PubMedCrossRef
44.
Zurück zum Zitat Tzellos T, Yang H, Mu F et al (2019) Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol 181:147–154PubMedCrossRef Tzellos T, Yang H, Mu F et al (2019) Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol 181:147–154PubMedCrossRef
45.
Zurück zum Zitat Vaiopoulos AG, Nikolakis G, Zouboulis CC (2020) Hidradenitis suppurativa in paediatric patients: a retrospective monocentric study in Germany and review of the literature. J Eur Acad Dermatol Venereol 34:2140–2146PubMedCrossRef Vaiopoulos AG, Nikolakis G, Zouboulis CC (2020) Hidradenitis suppurativa in paediatric patients: a retrospective monocentric study in Germany and review of the literature. J Eur Acad Dermatol Venereol 34:2140–2146PubMedCrossRef
46.
Zurück zum Zitat Vlassova N, Kuhn D, Okoye GA (2015) Hidradenitis suppurativa disproportionately affects African Americans: a single-center retrospective analysis. Acta Derm Venereol 95:990–991PubMedCrossRef Vlassova N, Kuhn D, Okoye GA (2015) Hidradenitis suppurativa disproportionately affects African Americans: a single-center retrospective analysis. Acta Derm Venereol 95:990–991PubMedCrossRef
47.
Zurück zum Zitat Wlodarek K, Glowaczewska A, Matusiak L et al (2020) Psychosocial burden of hidradenitis suppurativa patients’ partners. J Eur Acad Dermatol Venereol 34:1822–1827PubMedCrossRef Wlodarek K, Glowaczewska A, Matusiak L et al (2020) Psychosocial burden of hidradenitis suppurativa patients’ partners. J Eur Acad Dermatol Venereol 34:1822–1827PubMedCrossRef
48.
Zurück zum Zitat Zouboulis CC (2021) Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument. Br J Dermatol 184(6):1203–1204PubMedCrossRef Zouboulis CC (2021) Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument. Br J Dermatol 184(6):1203–1204PubMedCrossRef
49.
Zurück zum Zitat Zouboulis CC (2019) The socioeconomic burden of hidradenitis suppurativa/acne inversa. Br J Dermatol 181:7–8PubMedCrossRef Zouboulis CC (2019) The socioeconomic burden of hidradenitis suppurativa/acne inversa. Br J Dermatol 181:7–8PubMedCrossRef
50.
Zurück zum Zitat Zouboulis CC (2021) Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 35(7):1420–1421PubMedCrossRef Zouboulis CC (2021) Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 35(7):1420–1421PubMedCrossRef
51.
Zurück zum Zitat Zouboulis CC, Del Marmol V, Mrowietz U et al (2015) Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231:184–190PubMedCrossRef Zouboulis CC, Del Marmol V, Mrowietz U et al (2015) Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231:184–190PubMedCrossRef
Metadaten
Titel
Epidemiologie, Patientenlebensqualität und Behandlungskosten der Hidradenitis suppurativa/Acne inversa
verfasst von
Dr. N. Kirsten
V. Frings
G. D. Nikolakis
Dr. D. Presser
Prof. M. Goebeler
Prof. C. C. Zouboulis
Prof. M. Augustin
Publikationsdatum
05.07.2021
Verlag
Springer Medizin
Schlagwort
Acne inversa
Erschienen in
Die Dermatologie / Ausgabe 8/2021
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-021-04851-z

Weitere Artikel der Ausgabe 8/2021

Die Dermatologie 8/2021 Zur Ausgabe

Dermatoskopie – Fall des Monats

Blutung oder Melanom?

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.